NCT04206319View on ClinicalTrials.gov

Radium-223 in Biochemically Recurrent Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2027

Conditions
Biochemical Recurrent Prostate Cancer
Interventions
DRUG

Radium-223

an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days

DRUG

18F Sodium Fluoride

18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH